

T regulatory cells in chronic inflammatory response syndrome from water-damaged buildings (CIRS-WDB)

Ritchie Shoemaker, M.D.
Center for Research on Biotoxin
Associated Illnesses
Pocomoke, Maryland
9/6/2011

shoemaker
DIAGNOSIS • TREATMENT • RESEARCH • EDUCATION • GENOMICS

© Copyright and other intellectual property laws protect these materials. Reproduction or retransmission of the materials, in whole or in part, in any manner, without the prior written consent of the copyright holder, is a violation of copyright law. Purchase of this presentation is solely for personal, noncommercial use. Users may not distribute such copies to others, whether or not in electronic form, to any source.

What are regulatory T cells ?

- T lymphocytes; “T regs”
 - Thymus derived
 - Induced by TGF beta-1
- Suppress autoimmunity
- Suppress inflammation
- CD4+CD25+ markers
- FoxP3 as additional marker

Plasticity of T regs

- Hot topic in immunology
 - Literature is still evolving
- Conversion to Th 17
- Conversion to T memory cells
- FoxP3+ and FoxP3- cells
- Role of TGF beta-1 and presence of
 - IL6 leads to TH 17
 - ROR leads to T reg

Pathogenic T cells from T regs?

- Cellular basis of innate immunity!
- Potential to intervene in autoimmunity
- Potential to affect chronic inflammatory response syndromes
- Benefit from disease modulating drugs (especially MS and RA)

T regs in chronic illness

- Low levels in Post-Lyme, MS, RA, commensal staphylococcal infections, ciguatera, miscarriage, pre-eclampsia
- High levels in normal pregnancy
- Induced by interferon 1 beta, VIP, methotrexate and erythropoietin
- Lowered by IVIG, prednisone
- Do levels change after exposure to interior environment of water-damaged buildings (WDB)?

Hypotheses

- Low levels of T regs are seen in untreated CIRS-WDB
- Higher levels are obtained after treatment of CIRS-WDB
- Acute illness is associated with a fall in T regs; levels rise with treatment and re-Rx
- Treatment with vasoactive intestinal polypeptide (VIP) will further increase T reg levels

The study-1

- 350 patients treated in one clinic
- Exposure to WDB confirmed
 - Water intrusion and visible mold
 - Speciated filamentous fungi
 - All patients met GAO case definition
- Followed prospectively from baseline
 - Acute re-exposures documented
 - Chronic care

Methods

- Flow cytometry from Quest
 - Panel included CD4+; CD25+; and CD4+CD25+
- Insurance coverage
- No commercial FoxP3 assay
- Whole blood, refrigerated
- Not possible to use library of frozen specimens

Results-1

- Controls mean 21.3
- Cases baseline untreated 14.7
 - Adults 14.9
 - Peds 7.9
- Cases treated 21.2
- Relapse; previously treated 9.8
- Deliberate re-exposure 8.6
- After VIP 24.8

Sequential testing

- Controls no change
- Treated cases no change
- Monitoring over time identified 6 patients with unexplained fall
- Re-investigation of these identified WDB previously unsuspected

Deliberate re-exposure off meds

- Sequential Activation of Innate Immune Elements (SAIIE)
- Fall of T regs occurred on **Day 1**
- Levels did not spontaneously resolve
- Too few cases to clearly demonstrate link to TGF beta-1
- No data in literature on change in T regs from exposures

Conclusions-1

- Use of T regs adds additional marker for defining innate immune mechanisms in CIRS-WDB
- Baseline low levels are not diagnostic as a stand-alone test
- Treatment drives up T reg levels
- T regs fall in acute re-exposure
- VIP dramatically improves levels

Conclusions-2

- Weaknesses
 - No FoxP3 assay
 - Can't measure tissue levels
 - Can't identify pathogenic T cells
- Future use of T reg assays
 - Correlate with HLA DR
 - Expand use to multiple clinics
 - Identify mechanisms of acute and chronic changes